Navigation Links
Edimer Pharmaceuticals and CMC Biologics Announce Agreement to Manufacture EDI200 Recombinant Protein
Date:9/9/2010

CAMBRIDGE, Mass. and BOTHELL, Wash., Sept. 9 /PRNewswire/ -- Edimer Pharmaceuticals and CMC Biologics today announce the execution of a manufacturing contract to support the development of EDI200, a clinical-stage recombinant protein for the treatment of X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), a rare genetic disease with orphan designation in the USA and Europe.

(Logo:  http://photos.prnewswire.com/prnh/20100909/SF59797LOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100909/SF59797LOGO)

(Logo:  http://photos.prnewswire.com/prnh/20100824/SF54816LOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100824/SF54816LOGO)

CMC Biologics was selected by Edimer for their lead product due to its depth of expertise in protein development, analytical development and its cGMP manufacturing capabilities.

Neil Kirby, Ph.D., Edimer CEO, commented, "CMC's extensive experience in the GMP manufacture of therapeutic proteins makes them an ideal company to help us move this product forward. We believe that this product has the potential for making a difference in individuals' lives that currently have no available therapeutic options."

Gustavo Mahler, Ph.D., CMC Biologics Chief Operating Officer noted, "CMC is delighted to be able to assist Edimer in the development and production of this orphan protein. Our two teams are working together in an open and collaborative manner and we are excited about the project's potential."

About EDI200

Ectodysplasin-A1 (EDA-A1) is a signaling protein expressed in healthy individuals that is involved in the formation of sweat glands, teeth, hair and certain glandular structures. This protein is missing in patients with XLHED.  EDI200 is a form of EDA-A1 being developed by Edimer as a treatment for certain patients with XLHED.  EDI200 has been shown to substitute for lack of functional EDA-A1 protein in mouse and dog models of XLHED.

About Edimer Pharmaceuticals

Edimer Pharmaceuticals (www.edimerpharma.com)

Edimer is dedicated to deliver a significant and durable improvement in the health and quality of life to future generations affected by XLHED. Edimer was established in 2009 based on research conducted at the University of Lausanne, Switzerland. Edimer's lead product candidate, EDI200, represents the first of a new class of molecules designed to correct a developmental disorder in a pediatric population.

About CMC

CMC Biologics (www.cmcbio.com) is a leading contract development and manufacturing organization that provides fully integrated biopharmaceutical development and manufacturing services to clients around the world, from its facilities in Copenhagen, Denmark, and Seattle, WA.  The company specializes in custom services for the scale-up and cGMP manufacture of protein-based therapeutics for pre-clinical, clinical trials and in-market production.  CMC Biologics' wide range of integrated services includes cell line development using its proprietary CHEF1® system, process development and comprehensive analytical testing.  CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers both stirred tank and perfusion production processes.  


'/>"/>
SOURCE Edimer Pharmaceuticals; CMC Biologics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Transdel Pharmaceuticals to Present at Rodman & Renshaw 12th Annual Healthcare Conference
2. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare and Baird Global Healthcare Conferences
3. Access Pharmaceuticals Presents at American Chemical Society Annual Fall Meeting in Boston, MA
4. Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402.
5. NanoSmart™ Pharmaceuticals, Inc. Receives Patent Allowance for Tumor Targeting Platform Technology
6. CORRECTED: Ampio Pharmaceuticals Announces Completion of Negotiations for Acquisition of DMI BioSciences, Inc.
7. Vanda Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 5, 2010
8. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010
9. Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients
10. Amira Pharmaceuticals Hits Two Development Milestones Related to FLAP Inhibitor Program
11. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... ... Benchworks CEO Thad L. Bench Sr. will participate in the ... Diego. The event is a gathering of executive leadership from companies in the pharmaceutical, ... will also participate in the forum. Participants will discuss the future of the life ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Society for Immunotherapy of Cancer (SITC) ... the Administration’s recently published fiscal year 2018 budget request. , This proposal ... by $5.8 billion or roughly 20% of its total budget. If applied proportionally across ...
(Date:3/22/2017)... , March 22, 2017   Invitae Corporation ... genetic information companies, today announced the availability of ... Spinal Muscular Atrophy (SMA) , a neuromuscular ... genetic disorders among infants as well as a ... The new test, announced during the American College ...
(Date:3/20/2017)... ... March 20, 2017 , ... Existing ... preparation methods in order to reduce the impact on instrumentation. ICP-MS is a ... of elemental analysis. , This presentation will discuss the pros and cons ...
Breaking Biology Technology:
(Date:3/22/2017)... 21, 2017   Neurotechnology , a provider ... today announced the release of the SentiVeillance ... improved facial recognition using up to 10 surveillance, ... computer. The new version uses deep neural-network-based facial ... it utilizes a Graphing Processing Unit (GPU) for ...
(Date:3/22/2017)... Optimove , provider of the ... as 1-800-Flowers and AdoreMe, today announced two new ... Using Optimove,s machine learning algorithms, these features allow ... recommendations to their customers based not just on ... intent drawn from a complex web of data ...
(Date:3/22/2017)... Vigilant Solutions , a vehicle location ... announced today the appointment of retired FBI special agent ... business development. Mr. Sheridan brings more than ... focus on the aviation transportation sector, to his new ... Sheridan served as the Aviation Liaison Agent Coordinator (ALAC) ...
Breaking Biology News(10 mins):